Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study.

Cardiovasc Diabetol · 2025 · PMC12034169 · PMID 40287715

Europe PMC DOI

hedged sentence

0.1140

closest p · 2.3× alpha

0.1140

boldest claim

The sentences

a nonsignificant trendp = 0.114not close (p > 0.1)

For renal outcomes, CI-AKIESUR showed a nonsignificant trend pre-PSM (OR 0.941, 95% CI 0.887–0.998; p = 0.114), which was attenuated post-PSM (OR 0.779, 95% CI 0.492–1.233; p = 0.358).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.